29 September 2016 - The EMA has published an EPAR for Nordic Pharma's Nordimet.

Nordimet is indicated for the treatment of:

• active rheumatoid arthritis in adult patients
• polyarthritic forms of severe, active juvenile idiopathic arthritis, when the response to non-steroidal anti-inflammatory drugs has been inadequate
• severe recalcitrant disabling psoriasis, which is not adequately responsive to other forms of therapy such as phototherapy, psoralens and ultraviolet A, and retinoids, and severe psoriatic arthritis in adult patients

Read EPAR for Nordimet